[Problem] To provide an excellent therapeutic or prophylactic agent for cardiovascular diseases on the basis of cGMP production increasing activity attributed to soluble guanylate cyclase activating activity. [Solution] It was discovered that an imidazopyridine compound having a carbamoyl group at the 3 position of an imidazo[1 2 a]pyridine skeleton and having a substituent attached to the 8 position of the skeleton through an oxygen atom exhibits cGMP production increasing activity attributed to potent soluble guanylate cyclase activating activity and can be used in an excellent therapeutic or prophylactic agent for various cardiovascular diseases associated with soluble guanylate cyclase and the invention was completed.
